# Abu Dhabi Health Delegation Concludes Inaugural Visit to China, Opening New Pathways to Advance AI, Precision Medicine and Next-Gen Therapies

- Link: https://www.thailand-business-news.com/pr-news/abu-dhabi-health-delegation-concludes-inaugural-visit-to-china-opening-new-pathways-to-advance-ai-precision-medicine-and-next-gen-therapies
- Published: 2026-10-18T00:54:00+07:00
- Author: PR Newswire

|   |

ABU DHABI, UAE, Oct. 18, 2026 /PRNewswire/ — The Department of Health – Abu Dhabi(
DoH), the regulator of the healthcare sector in the emirate, has concluded its inaugural
health and life sciences mission to China, advancing priority areas of collaboration
designed to accelerate the translation of scientific and technological innovation
into better health outcomes. The mission brought Abu Dhabi’s health and life sciences
ecosystem together with leading Chinese healthcare institutions, universities and
innovators through 32 meetings and site visits across Beijing, Shanghai and Shenzhen.

 [⌊Abu Dhabi Health Delegation Concludes Inaugural Visit to China, Opening New Pathways to Advance AI, Precision Medicine and Next-Gen Therapies⌉](https://mmx.prnasia.com/media/MS2015526/Abu-Dhabi-Health-Delegation-Concludes-Inaugural-Visit-to-China-Opening-New-ID-993839ebc3f5.jpg?id=OA3025046&p=medium600)

Abu Dhabi Health Delegation Concludes Inaugural Visit to China, Opening New Pathways
to Advance AI, Precision Medicine and Next-Gen Therapies

Moving beyond technology exchange, discussions identified opportunities to connect
China’s scientific, technological and manufacturing capabilities with the Emirate’s
integrated healthcare ecosystem, population-scale data and genomics, clinical infrastructure
and agile regulatory environment.

**H.E. Dr. Noura Khamis Al Ghaithi, Undersecretary of DoH,** said: "Shaping the 
future of healthcare requires health ecosystems to connect scientific discovery 
and evidence with effective implementation and access to care. Innovation alone 
cannot transform healthcare. China brings exceptional scientific, technological 
and manufacturing capabilities, while Abu Dhabi offers an integrated environment
where innovation can be developed, validated, applied and responsibly scaled. Through
this mission, we have identified clear opportunities to combine these strengths 
across artificial intelligence, precision medicine, advanced therapies and diagnostics."

Across engagements with leading biotechnology and pharmaceutical companies, the 
delegation explored opportunities to accelerate the development and accessibility
of next-generation treatments. Discussions spanning advanced cell therapies, biologics,
drug discovery and organoid-based research examined opportunities for clinical research,
evidence generation and knowledge transfer. The mission also explored how Abu Dhabi’s
diverse patient population, genomic capabilities and clinical research environment
could support the validation of therapies across different populations and help 
shorten the pathway from scientific discovery to patient access.

Through engagements spanning AI-native hospitals, surgical robotics, laboratory 
automation, advanced imaging and brain-computer interfaces, discussions explored
potential pathways for clinical evaluation, joint development, specialised training
and responsible technology adoption. This included opportunities to move beyond 
individual AI applications towards connected healthcare intelligence across the 
patient journey, as well as exploring how advanced surgical and diagnostic technologies
could be validated within Abu Dhabi’s clinical environment and potentially scaled
internationally.

Precision oncology was another major focus, with engagements exploring how advanced
molecular diagnostics, imaging, genomics and AI could transform the cancer pathway
from earlier screening and diagnosis through treatment selection and recurrence 
monitoring. Discussions considered how Chinese diagnostic innovation could connect
with Abu Dhabi’s genomic, health-data and clinical research infrastructure to validate
emerging technologies across diverse populations, generate new evidence and accelerate
their integration into clinical practice.

Building on Abu Dhabi’s existing genomics and biobanking capabilities, engagements
also explored opportunities to connect population-scale biological data with advanced
multi-omics, AI and research capabilities. Potential areas of collaboration include
deepening understanding of diseases affecting local populations, supporting earlier
identification of health risks, shortening diagnostic journeys for rare diseases
and accelerating the development of more precise diagnostics, treatments and prevention
strategies.

---

  |  This article was produced by Cision PR Newswire, our trusted news partner. The views expressed and the content presented here are solely those of the author and may not fully reflect the opinions of Thailand Business News. |

---

 
**Read the original article :** [Abu Dhabi Health Delegation Concludes Inaugural Visit to China, Opening New Pathways to Advance AI, Precision Medicine and Next-Gen Therapies ](http://www.prnasia.com/story/archive/5074804_AE74804_0?rand=184833)